Diagnostic utility of lymphocyte enhancer factor 1 in aggressive B-cell lymphoma with MYC rearrangement
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae189 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Xin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA. Hauptthemen laut MEDLINE: Lymphoid Enhancer-Binding Factor 1, Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-myc, Biomarkers, Tumor. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Albany medical college.
Abstract (Originalsprache)
Objectives
We sought to investigate the diagnostic value of lymphocyte enhancer factor 1 (LEF1) expression in aggressive B-cell lymphomas (BCL) with MYC gene rearrangement (MYC-R).
Methods
Sixty-seven cases of BCL were studied and included Burkitt lymphoma (BL) (23 cases); diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) with MYC-R (13 cases); and DLBCL/high-grade B-cell lymphoma with MYC, BCL2, and/or BCL6 rearrangements (double-hit [DH] or triple-hit [TH], 17 cases). Random DLBCL-NOS (14 cases) without MYC-R was recruited as a control group. By immunohistochemical stains, 3 patterns of LEF1 staining were recorded as pattern 0 (negative), pattern 1 (weak and heterogeneous staining, <80%), and pattern 2 (moderate/strong and uniform staining, ≥80%).
Results
Pattern 1 can be seen in all BCLs with MYC-R included in this study and more commonly seen in DLBCL without MYC-R (8/14 cases). Pattern 2 is characteristic (positive predictive value = 86%) for Epstein-Barr virus (EBV)–negative BL, while pattern 0 was seen in 22 (76%) of 29 cases of DLBCL-MYC-R/DH/TH (P < .001). Seven of 8 EBV-positive BL cases showed pattern 0, which was completely opposite to the common pattern 2 in EBV-negative BL (12/15 cases). Pattern 2 was not detected in all DH/TH cases.
Conclusions
Weak and heterogeneous staining of LEF1 can be seen in all the BCLs with and without MYC-R. Strong and uniform staining of LEF1 is highly characteristic of EBV-negative BL among all aggressive BCLs with MYC-R, while the negative staining of LEF1 is mostly suggestive of DLBCL-MYC-R/DH/TH. Lymphocyte enhancer factor 1 provides additional diagnostic value in the differentiation of BL from other aggressive BCLs with MYC-R, especially in a limited specimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.
Förderung
- Albany medical college
Zitieren
APA
Wang, X., Faraz, M., Chen, A., Nazeer, T., & Huang, X. (2025). Diagnostic utility of lymphocyte enhancer factor 1 in aggressive B-cell lymphoma with MYC rearrangement. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae189
Vancouver
Wang X, Faraz M, Chen A, Nazeer T, Huang X. Diagnostic utility of lymphocyte enhancer factor 1 in aggressive B-cell lymphoma with MYC rearrangement. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae189
BibTeX
@article{Wang2025,
author = {Wang, Xin and Faraz, Maria and Chen, Anne and Nazeer, Tipu and Huang, Xiaoyan},
title = {Diagnostic utility of lymphocyte enhancer factor 1 in aggressive B-cell lymphoma with MYC rearrangement},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae189}
}
EUVIMED